astragaloside IV

Overview

Astragaloside IV (AS-IV) is a naturally occurring cycloartane-type triterpenoid saponin isolated primarily from Astragalus membranaceus (Astragalus radix, AR), a root herb widely used in traditional Chinese medicine. Structurally, it belongs to the astragaloside family — a group of bioactive saponins that includes astragaloside I (AS-I), astragaloside II (AS-II), astragaloside III (AS-III), and the aglycone cycloastragenol (CA) — each exhibiting distinct pharmacological profiles and in vivo exposure characteristics. AS-IV is recognized for its anti-inflammatory, neuroprotective, and cardioprotective properties, and has attracted substantial research interest as a candidate for multi-symptom therapeutic strategies in complex chronic diseases.

Mechanistically, AS-IV exerts its effects through modulation of inflammatory signaling cascades, mitochondrial biogenesis pathways, and energy metabolism networks. A key molecular target is toll-like receptor 4 (TLR4), a pattern recognition receptor central to innate immune activation and neuroinflammation. By suppressing TLR4-mediated signaling, AS-IV can attenuate the production of proinflammatory cytokines and downstream inflammatory cascades. Additionally, AS-IV influences mitochondrial-synaptic homeostasis through axes such as GSK-3β/PGC-1α, situating it as a compound capable of addressing both upstream inflammatory triggers and downstream metabolic and synaptic dysfunction.

Recent Publications Focus

Below is a summary of the newest research publications targeting astragaloside IV (sorted by publication date).

Recent investigations have demonstrated the multifaceted therapeutic potential of astragaloside IV across diverse biomedical applications. A landmark study in 2026 developed a vascular-targeted DNA nanoplatform (TDN@Ast-AptCD34) to enhance the delivery of AS-IV, leveraging its inherent pro-angiogenic and osteogenic properties [PMID 41713052]. This delivery system was designed to facilitate distraction osteogenesis through activation of the E2F2/PI3K/AKT/FOXO signaling pathway, demonstrating how nanotechnology can optimize the bioavailability and efficacy of natural compounds.

In neurodegenerative disease research, AS-IV has shown promise in attenuating neuroinflammatory pathology. A murine Parkinson's disease model revealed that astragaloside IV alleviates both motor deficits and anxiety-like behaviors by targeting TLR4-mediated neuroinflammation [PMID 41846059]. This mechanism capitalizes on AS-IV's documented anti-inflammatory properties, positioning it as a candidate therapeutic for neurobehavioral dysfunction associated with proinflammatory cytokine dysregulation in neurodegenerative conditions.

Pharmacokinetic characterization has further established the clinical relevance of astragalosides. A comprehensive in vivo study discriminated the significance of multiple astragalosides (astragaloside I, II, III, IV, and cycloastragenol) in Astragalus radix, correlating their exposure levels with diverse pharmacological activities and establishing quality markers for standardization in therapeutic applications [PMID 41734824].

Cardiovascular applications have also benefited from AS-IV investigation. AS-IV was identified as an active constituent in the Yangxinshi formula, which protects against post-myocardial infarction heart failure with reduced ejection fraction through improvement of energy metabolism via inhibition of FOXO1/PDK4 signaling [PMID 42062031]. This finding highlights the role of adenosine triphosphate metabolism in AS-IV's cardioprotective mechanism.

At the cellular level, astragaloside IV demonstrates regenerative potential through stem cell modulation. Pretreatment of bone marrow mesenchymal stem cells (BMSCs) with AS-IV, a principal bioactive compound in herbal formulations such as HQI, enhanced their therapeutic efficacy in fulminant hepatic failure models by promoting stemness-related gene expression, improving cell cycle progression, and conferring resistance to LPS-induced apoptosis [PMID 42417943]. This suggests that AS-IV may function as a cell conditioning agent to optimize the therapeutic properties of cell-based therapies.

Phytochemical quality assessment has identified astragaloside A as one of multiple quality markers in complex herbal preparations such as Yupingfeng, supporting the utility of chromatographic and spectrometric methods for standardization and potency verification of herbal formulations containing astragalosides [PMID 41925119].